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KEY POINTS
 Early recognition and escalation of care with mechanical circulatory support are crucial for
patients presenting with cardiogenic shock due to structural heart disease.
 Selection of mechanical circulatory support methods should be based on device availability,
familiarity of the multidisciplinary team with the device, and specific needs of the patient.
 Surgical or transcatheter repair of structural heart disease should be done using appropriate
mechanical support with a “heart team” approach after the patient has improved.
Tremendous advances in all forms of cardiovas-
cular care1 have developed over the past
decade, with remarkable and dramatic declines
in cardiovascular mortality (between 60% and
70%).2 Despite such advances in cardiovascular
disease therapies, cardiogenic shock (CS) is a
common cause of mortality, and management
of CS remains challenging. Acute coronary syn-
drome accounts for more than 80% of cases of
CS.3 As a result, interest in CS has predomi-
nantly focused on managing acute coronary syn-
drome, including revascularization. Few studies
to date have explored the role of structural heart
disease (SHD) in the pathogenesis of CS. In the
SHOCK (should we emergently revascularize
occluded coronaries for cardiogenic shock) trial
registry of 1190 patients with CS, 8% of patients
had SHD that caused or worsened their hemody-
namic status, with a mortality close to 100%.4
Similar poor outcomes have been observed in
other observational studies.5–7
Temporary mechanical circulatory support
(MCS) is an attractive and intuitive option to
use when other medical therapies have been
insufficient. Many exciting developments in
MCS methods have occurred in the past few
years, including the development of smaller
portable pumps.8 Although the field is a
growing one, patients with SHD are often
excluded from randomized trials, and the role
of mechanical therapies in this specific popula-
tion remains controversial and not well
established.
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SHD refers to non–coronary heart disease for
which some therapy, surgical or percutaneous,
exists. Examples include valvular heart disease,
congenital disorders, mechanical complication
of acute myocardial infarction, and cardiomyop-
athies.9 Although the treatment of SHD often re-
quires pharmacologic and surgical intervention,
established and emerging device-based inter-
ventions in the setting of CS offer exceptional
promise for revolutionizing the practice of car-
diovascular medicine. Nevertheless, when pa-
tients with SHD present with CS, treatment
becomes more challenging and complex.
Currently, there are no published guidelines
for using MCS in patients with SHD. The focus
of this review is on MCS device selection, specif-
ically, selection pathways for patients with CS
from SHD. The objective is to provide the reader
with an understanding of general consider-
ations, based on current evidence and institu-
tional experience, for determining the
appropriateness of MCS for SHD.
HEART TEAM
With the number of therapeutic options
increasing, the “heart team” has become an
increasingly important strategy for evaluating
SHD, whereby comprehensive decision making
may result in a change of diagnostic or therapeu-
tic strategies and promote improved outcomes.
Several guidelines have highlighted the effect of
heart teams for managing valvular heart disease
and heart failure.10–14 Determining an optimal
treatment strategy for patients with complex
SHD and CS requires assessing each patient’s
presenting illness, clinical stability, anatomy,
comorbidities, and goals of care. Implementing
the scarce guidance available to guide SHD-CS
management to the nuances of real-world prac-
tice can be challenging; thus, supporting an
interdisciplinary model of care is key.
DEFINITION OF CARDIOGENIC SHOCK
The American Heart Association defines CS as a
state in which ineffective cardiac output caused
by a primary cardiac disorder results in both
clinical and biochemical manifestations of inad-
equate tissue perfusion and dysfunction. In
addition to severe systolic and diastolic cardiac
dysfunction compromising macrocirculation
and microcirculation, systemic inflammatory
response syndrome and even sepsis may
develop, which could result in multiorgan
dysfunction syndrome and biochemical mani-
festations of inadequate tissue perfusion, such
as elevated arterial lactate. The most common
hemodynamic criteria for CS include a systolic
blood pressure less than 90 mm Hg, a cardiac
index less than 2.2 L/min/m,2 a pulmonary capil-
lary wedge pressure greater than 18 mm Hg, or
a right ventricular (RV) end diastolic pressure
greater than 10 to 15 mm Hg. Although
myocardial infarction with left ventricular (LV)
failure remains the most common cause of CS,
any acute cause of severe LV or RV dysfunction
may lead to CS.15
HEMODYNAMIC MONITORING
Although not mandatory in clinical practice,
assessing objective hemodynamic parameters,
such as reduced cardiac index and elevated pul-
monary capillary wedge pressure, is helpful for
diagnosing CS, and other hemodynamic param-
eters are essential for defining RV function in
CS.16 A large national US registry showed that
assessing premature atrial contractions in pa-
tients with CS is an effective strategy, and using
this method is associated with improved out-
comes, which may reflect better selection of pa-
tients or better use of the information to guide
therapies.17 To improve patient outcomes, the
authors recommend assessing hemodynamic pa-
rameters using premature atrial contractions in
patients with SHD-CS for monitoring guiding
treatment effectiveness.
MEDICAL THERAPY
Disease management in patients with CS should
focus on maintaining adequate cardiac output
for vital end-organ perfusion. For patients with
acute coronary syndrome with CS, therapy for
patient-specific cause should focus on coronary
reperfusion and treatment of the underlying
SHD that is causing the CS or is a consequence
of myocardial infarction. Urgent revasculariza-
tion and surgical/transcatheter therapies remain
the gold standard of care for CS; however, pa-
tients often are unstable with increased mortality
to receive a definitive therapy. SHD-specific
definitive interventions will not be discussed
because they are beyond the scope of this
review.
Pharmacotherapies, such as inotropes and va-
sopressors, are used to enhance contractility and
modulate vascular tone. Maximal medical ther-
apy (volume resuscitation, vasodilators,
inotropic agents) is not considered a justifiable
endpoint for refractory CS, at least in well-
resourced health settings.18 The lack of clear ev-
idence on the effectiveness of pharmacologic
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inotropic support and the limited (or adverse) ef-
fect of catecholamine therapy on survival in pa-
tients with CS from acute myocardial
infarction19,20 are the driving forces behind
exploration of mechanical means of circulatory
support.21
The authors believe that physicians treating
patients with SHD should adhere to recommen-
dations similar to those recently proposed by
the European Acute Cardiovascular Care Associ-
ation for patients with acute coronary syndrome
complicated by CS, such as the following: (1)
When severe SHD is diagnosed and is contrib-
uting to instability, the patient should be
admitted or transferred to a hospital that has
24/7 MCS capability to treat the impending car-
diovascular crisis; (2) catecholamine and ino-
tropes should be administered at the lowest
possible dose and for the shortest possible dura-
tion; (3) the routine use of intra-aortic balloon
pump is not recommended, whereas the use of
percutaneous MCS devices should be restricted
to cases of refractory CS, with treatment being
guided by individual physician experience in
dedicated centers; and (4) in addition to the
general principles of RV dysfunction manage-
ment, the use of MCS devices with dedicated
RV support or venous arterial extracorporeal
membrane oxygenation (VA-ECMO) may be




Temporary selection of MCS should be based
on device availability, familiarity of the multidis-
ciplinary team with the device, and specific pa-
tient needs.8 In the United States, temporary
percutaneous mechanical options for drug-
refractory CS have included the following
methods: intra-aortic balloon pump, counter-
pulsation, and percutaneous LV assist devices.
Specific LV assist devices include the Tandem-
Heart percutaneous system (Cardiac Assist,
Inc, Pittsburgh, PA, USA), the Impella (Abiomed
Europe GmbH, Aachen, Germany), and VA-
ECMO.23 A variant of VA-ECMO is left atrial
venoarterial extracorporeal membrane oxygen-
ation (LAVA-ECMO), which is a novel technique
that involves transseptal placement of a single
multistage drainage venous femoral cannula to
simultaneously drain both atria in patients with
severe LV systolic dysfunction.24 For RV failure,
right-sided support devices, such as Impella RP
and the TandemHeart RA-PA, are available op-
tions in addition to ECMO.23 Fig. 1 shows
schematic drawings of current percutaneous
mechanical support devices for CS, including
technical features.
AORTIC STENOSIS
Aortic stenosis is the most common valvular
heart disease causing LV outflow tract obstruc-
tion. Pressure gradient and LV pressure overload
are the hallmarks of severe aortic stenosis that
cause leaflet stretch, fluid shear stress, bending
stresses, and pressure forces. This tissue dam-
age results in elevated left atrial pressure and
pulmonary capillary wedge pressure. Over
time, some patients may develop LV dysfunction
because of increased wall stress secondary to
inadequate wall thickening, potentially resulting
in “afterload mismatch.”25,26 Patients with se-
vere aortic stenosis, LV dysfunction, and unre-
vascularized coronary artery disease are
particularly susceptible to hemodynamic decom-
pensation owing to limited myocardial reserve.27
The incidence of CS in patients with aortic ste-
nosis is low (close to 6%),28 but mortality in pa-
tients who have developed CS can be
considerably high, up to 70%, if no durable inter-
vention is performed.29 Therapeutic interven-
tions for CS related to aortic stenosis are
challenging because of a paucity of data.
Whereas medical treatment alone is an unreli-
able option, and surgery is often deemed pro-
hibitive, it is unclear whether direct
transcatheter aortic valve replacement (TAVR)
or balloon aortic valvuloplasty (BAV) followed
by elective TAVR or surgical aortic valve replace-
ment (SAVR) after medical stabilization should
be performed. Medical therapy for patients
with aortic stenosis and CS should include
optimal ventilatory and inotropic support, and
every effort should be made to identify and treat
the precipitating factors. Treatment options for
aortic stenosis with CS include surgery or urgent
TAVR.30 Despite recent advances in therapies,
caring for patients with severe aortic stenosis
who go on to develop systolic dysfunction and
CS remains an important clinical challenge, and
this condition is associated with increased
morbidity and mortality.30,31
Over the past decade, Impella has become
commercially available for providing circulatory
support in patients with aortic stenosis.32 A rela-
tive contraindication for using the Impella device
is a concern about potential compromise of
blood flow in the remaining valvular orifice
from the presence of a catheter, which could
lead to worsened hemodynamics through a
severely stenotic aortic valve orifice. Regardless,
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the use of Impella has been shown to be
feasible, with promising results seen in selected
patients with severe aortic stenosis.33 The
Impella device directly aspirates blood from
the LV into the aorta in series with the native car-
diac blood flow. Owing to the unique design,
this device effectively unloads the LV and simul-
taneously stabilizes the patient’s hemodynamics
and augments cardiac output. Implantation of
the 2.5, 3.5, and 5.0 left-sided Impella seems
to be feasible in patients with severe aortic ste-
nosis, and a balloon-assist technique may be
used to facilitate device implantation when initial
unassisted attempts have failed. Improved he-
modynamic stability may enhance the tolerability
of lengthy and complex procedures by unload-
ing the LV.34,35 In cases of CS with concomitant
coronary artery disease, the risk of the decom-
pensation is higher,36 but MCS with Impella
can improve distal coronary pressure and coro-
nary perfusion pressures in the presence of crit-
ical coronary stenosis.37 Fig. 2A shows
schematic drawings of current percutaneous me-
chanical support devices for aortic stenosis in
CS.
Several single-center studies have demon-
strated the feasibility of using BAV as a bridge
to TAVR and SAVR in patients with acute presen-
tations and as a way to triage select high-risk
patients who are not good candidates for aortic
valve replacement.38,39 When BAV is performed
and the ventricles are paced at high rates, a sud-
den decrease in stroke volume and cardiac
output causing ischemic and hemodynamic
strain may result during the procedure, and
these results may be due to periods of hypoten-
sion with subsequent systemic and coronary
hypoperfusion. BAV can be done with the
Impella device in place to minimize interruption
of blood flow during balloon inflation and during
high-risk BAV40,41 (Fig. 3). Furthermore, evi-
dence exists that points to a similar cerebrovas-
cular risk in patients undergoing BAV or TAVR,
with the central venous access device registry
reporting an adverse event rate of 1.72% at
30 days following Impella-assisted BAV.36
Peri-interventional CS is associated with high
mortality and can occur during TAVR in a variety
of scenarios, such as coronary obstruction, re-
fractory ventricular arrhythmia, annular rupture,
and hemodynamic collapse.33,42 In a study of
54 patients who required an MCS device during
TAVR, Impella was used in only 7 patients: 3
elective cases and 4 emergency rescues. The
overall in-hospital mortality in this study was
11% for elective cases and 53% for emergency
rescue. CS was the cause of death in 50% of
cases, and all-cause mortality at 1 year was
Fig. 1. Current percutaneous mechanical support devices for CS. IABP, intra-aortic balloon pump. (Adapted from
Thiele H, Ohman EM, de Waha-Thiele S, Zeymer U, Desch S. Management of cardiogenic shock complicating
myocardial infarction: an update 2019. Eur Heart J. 2019;40(32):2671-2683; with permission.)
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Fig. 2. Recommended algorithm for
MCS utilization for SHD: (A) aortic steno-
sis, (B) AR, (C) mitral stenosis, (D) mitral
regurgitation, and (E) VSD.
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19% for elective cases and 71% for emergency
cases.43 In situations wherein Impella has not
been available, ECMO has been used for bailout
in TAVR use complicated by CS44 (Fig. 4).
AORTIC REGURGITATION
Aortic regurgitation (AR) causes volume over-
load of the LV. Over time, LV end-diastolic vol-
ume continues to increase; the ejection fraction
Fig. 3. Impella CP device-assisted
BAV in a patient with CS and severe
aortic stenosis. (Courtesy of
ABIOMED Inc., Danvers, MA.)
Fig. 4. Combined use of percuta-
neous ECMO and Impella CP in a
case of periprocedural coronary oc-
clusion in a valve-in-valve TAVI
(blue arrow: venous ECMO cannula;
red arrow: Impella CP in the left
ventricle). (Impella CP courtesy of
ABIOMED Inc., Danvers, MA.)
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drops, and these changes may precede the
appearance of clinical symptoms. Acute AR can
be life threatening, as LV dilatation and other
compensatory mechanisms cannot develop
rapidly enough to prevent hemodynamic deteri-
oration. Regarding the medical management of
AR in the setting of CS, stabilization with airway
intubation and hemodynamic support may be
required, especially before intervention. The
use of vasodilators, such as nitroprusside, in
conjunction with inotropic therapy may help
with hemodynamic stabilization.45 Pacing after
BAV and TAVR has been adopted as temporary
or permanent therapy to mitigate perivalvular
leak in patients affected by moderate to severe
AR.46 This approach is based on the concept
that a shorter diastolic phase reduces the time
available for blood to flow back into the
ventricle, thus diminishing the ventricular over-
load. Prompt SAVR remains the standard of
care for operable patients; however, TAVR has
been used in selective cases.47
Unfortunately, given the pathophysiology of
the disease, most (if not all) MCS have a relative
contraindication in the setting of severe AR.
Management of CS with acute AR with an
Impella or intra-aortic balloon pump device
would not provide adequate circulatory support
or mitigate aortic insufficiency. If MCS is
mandated, the TandemHeart device could be
considered, although it indirectly unloads LV vol-
ume by actively unloading the left atrium; how-
ever, the AR may remain unaffected or could
be worsened because of pressurized blood in
the aorta, increasing the retrograde flow. At
the authors’ center, they have used Tandem-
Heart as a bridge to surgery, considering the
limitations mentioned above. Case reports
describing use of TandemHeart with off-label
use of an Amplatzer occluder device to limit
AR have reported mitigation of the acute phase
as a bridge to surgery.48 Another possibility for
treating severe AR is the LAVA-ECMO, as it
might be better for unloading the LV than the
standard VA-ECMO because it offers sufficient
biventricular decompression.
MITRAL STENOSIS
The incidence of CS in patients withmitral stenosis
isunknownbut isprobablyvery low inwealthier na-
tions, despite being a highly prevalent condition
worldwide. It occurs mainly in patients who have
not received treatment until the mitral stenosis is
very advanced, with CS being the final manifesta-
tion. Mortality can reach close to 25% if it is not
treated accordingly. The key hemodynamic conse-
quence of mitral stenosis is the development of a
Fig. 5. LAVA ECMO in a patient
with biventricular failure and severe
mitral regurgitation. The multistage
cannula (arrow) drains in both the
left atrium via end hole (red circle)
and right atrium via side holes
(blue circle).
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pressure gradient between the left atrium and LV,
which is transmitted to the pulmonary circulation
and results in an increase in both pulmonary pres-
sures and pulmonary vascular resistance, resulting
in pulmonary edema, RV failure, and CS. A rapid
diagnosis of this condition is important because
emergency interventions, such as valve replace-
ment or percutaneous balloonmitral valvuloplasty
(PBMV), are effective and readily available. Only a
fewcaseseries have reported successful treatment
of CS with PBMV.49–51 The most commonly
encountered occurrence is an underlying mitral
stenosis affected by septic or hypovolemic shock,
which may trigger CS.
Medical treatments to stabilize patients with
mitral stenosis include optimal ventilatory and
inotropic support. Excessive tachycardia in these
patients shortens diastole and causes an unde-
sired increase in pressure gradients across the
mitral valve. When a patient’s condition remains
unstable despite treatment of precipitating fac-
tors, emergent mechanical relief of mitral steno-
sis should be done as soon as possible with
either PBMV or surgery. If inappropriate valvular
anatomy precludes PBMV or surgery, or if a
contraindication for PMBV exists, the device of
choice should be TandemHeart. This MCS facili-
tates hemodynamic stabilization by directly
unloading the left atrium and promoting decon-
gestion of the lungs, which facilitates a bridge to
mitral valve surgery. If there is RV failure and
hypoxemia, the CS mitral stenosis can be
treated with VA-ECMO, with the preferred use
of the LAVA-ECMO modality that decompresses
both atriums and pulmonary filling pressures.
MITRAL REGURGITATION
Acutemitral regurgitation isa rarebut lethal condi-
tion that often results in CS and high mortality,
especially in the setting of acute coronary syn-
drome (10% to 40%with surgery; 80%without sur-
gery).4,52,53 Urgent surgical mitral repair or
replacement is the current standard of care; how-
ever, a significant portion of patients do not
receive surgery because of prohibitive operative
risk or inability to be stabilized before surgery.4,54
As a result, large randomized studies of this phe-
nomenon are difficult to perform, and evidence
of treatment is limited to case reports, even for
the current gold standard of surgery.53,55 Mitra-
Clip has been previously reported for treating
acute mitral regurgitation after myocardial infarc-
tion or with CS, with most cases being poor LV
function.56–60
Recently improved MCS could potentially sta-
bilize patients with acute mitral regurgitation
and serve as a bridge to definitive treatment.61
The preoperative implantation of MCS seems to
improve outcomes in patients with CS who are
Fig. 6. Combined use of percuta-
neous TH-RAPA and Impella CP in
a case of severe mitral regurgitation
secondary to chordae rupture post
myocardial infarction treated percu-
taneously with edge-to-edge repair
(blue arrow: venous TH-RAPA can-
nula; red arrow: Impella CP in the
left ventricle; yellow arrow: Mitra-
Clip system). (TandemHeart RAPA
courtesy of TandemLife; LivaNova,
London, UK; Impella CP courtesy of
ABIOMED Inc., Danvers, MA; Mitra-
Clip courtesy of Abbott Vascular,
Santa Clara, CA, USA).
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suitable for urgent surgery62,63 and is generally
accepted as the standard of care until emergent
mitral valve surgery can be performed. The
intra-aortic balloon pump has been a commonly
used device, although it offers the least cardiac
output augmentation; however, it is widely avail-
able and can decrease afterload, thereby sup-
porting adequate mean arterial pressure and
potentially decreasing the mitral regurgitation.
The Impella device, used alone or together with
ECMO (ie, ECPELLA), offers more significant car-
diac output augmentation and directly unloads
the LV. On the other hand, ECMO has been
less commonly used alone, as it may increase to-
tal peripheral vascular resistance, potentially
worsening the mitral regurgitation. In cases
whereby only ECMO is available, physicians
should consider the LAVA-ECMO modality to un-
load the left atrium (Fig. 5). The TandemHeart
device can directly unload the left atrium and
potentially offer the best hemodynamic effect in
patients with acute mitral regurgitation. However,
MCS use has not been without risk, and it has
been reported to directly cause chordal rupture




Ventricular septal defect or rupture (VSD) is an
infrequent but lethal complication of acute
myocardial infarction.65 When VSD is associated
with CS, the mortality is greater than 80%.66 The
definitive therapy for VSD is surgical repair or
use of percutaneous closure devices for eligible
patients.67 Inotropes and vasopressors worsen
left-to-right shunting, whereas vasodilators
decrease shunting at the expense of worsening
hypotension. Frequently, very ill patients with
VSD and CS will need hemodynamic stabilization
with MCS to improve systemic perfusion. Most
of the available MCS devices, including intra-
aortic balloon pump,68 ECMO,69,70 Tandem-
Heart,71,72 and Impella (including 5.0 support),
have been used to treat unstable patients with
VSD and CS.73,74 Despite widespread use of
percutaneous MCS, guidelines for optimal use
have not been defined because the low inci-
dence and high acuity of VSD have made ran-
domized clinical studies almost impossible to
conduct. The European Society of Cardiology
Guidelines categorize VSD with CS as a class
IIa recommendation (level of evidence C) and
suggest using short-term MCS therapy as a
bridge to recovery or surgery; however, the
guidelines do not specify a preferred form of
support.75
A computer-simulation model assessing he-
modynamic effects of MCS in VSD showed that
no form of MCS could normalize hemodynamics
in the setting of VSD whereby blood flow
through the pulmonary artery (PA) was always
markedly elevated. This hemodynamic
Fig. 7. Proposed algorithm for hemodynamic monitoring and initiation of MCS in those patients presenting with
CS due to SHD. ACS, acute coronary syndrome; CI, cardiac index; CO, cardiac output; CPO, cardiac power output;
PAPI, pulmonary artery pulsatility index; PCI, primary cutaneous intervention; RHC, right heart catherization.
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phenomenon may occur because of increased
left-to-right shunting through the VSD or
increased right-sided venous return from
increased systemic flow in the presence of left-
sided support provided by the MCS device.
However, this model showed that a combination
of 2 devices can provide the greatest degree of
overall circulatory support while simultaneously
unloading the LV (ie, ECPELLA), with the Impella
5.0 being the most effective MCS and the intra-
aortic balloon pump being the least effective
MCS.76 One clinical feature that favors use of
an ECMO approach is significant hypoxemia.
RIGHT-SIDED STRUCTURAL HEART
DISEASE
CS secondary to isolated right-sided SHD is rare,
as this disease can be well tolerated over time.
However, left-sided SHD commonly manifests
with right RV failure, which increases short-term
mortality.77,78 Diagnosing acute RV failure re-
mains a major clinical challenge. Physical exami-
nation, echocardiography, and laboratory tests
are helpful tools; however, assessment of pre-
mature atrial contractions with other well-
established indexes of RV failure can help to
confirm diagnosis. Intra-aortic balloon pumps
are commonly used to treat RV failure but are
not optimally suited for this purpose. Recent ad-
vances in percutaneous technology have
brought multiple devices into practice that allow
rapid deployment of percutaneous RV mechani-
cal support. These devices are categorized ac-
cording to their mechanism of action, such as
direct RV bypass or indirect RV bypass systems.
The Impella RP and the TandemHeart RAPA
(TH-RAPA) displace blood from the right atrium
to the PA, directly bypassing the RV79,80 (Fig. 6).
In contrast, VA-ECMO displaces and oxygenates
blood from the right atrium to the femoral ar-
tery, thereby indirectly bypassing the RV. As a
result, these systems have distinct hemodynamic
effects, depending on whether the patient has
isolated RV failure or biventricular failure.
Because RV MCS device options have been
recently introduced, no specific guidelines for
optimal device selection and management exist.
FUTURE DIRECTIONS: PROPOSED
ALGORITHM
Based on the existing literature and the authors’
clinical experience, they have proposed and rec-
ommended an algorithm for the use of MCS de-
vices for each SHD discussed in this review
(Fig. 2). To guide the management of CS owing
to SHD, the authors encourage adopting an early
consultation with the heart team to determine an
optimal management strategy on a case-by-case
basis. They advocate the recognition of CS and
early use of percutaneous MCS when indicated
based on objective hemodynamic and perfusion
parameters to prevent progressive deterioration
and organ hypoperfusion. Defining which MCS
is the best option should be determined by the
main underlying condition and the presence or
absence of RV failure and/or hypoxemia. MCS
may be considered a temporizing therapy for
transcatheter options or potentially as a bridge
to surgery or transplant after patient stabilization
(Fig. 7).
SUMMARY
Treatment of SHD in the setting of CS remains
challenging. Many advances have improved
diagnosis and therapy for SHD in CS. Early use
of MCS devices instead of dose escalation of
inotropes and vasopressors might prevent dis-
ease progression and reduce mortality in pa-
tients with SHD complicated with CS.
Appropriate device selection is still a complex
decision-making process, and the authors
expect that ongoing studies that take into ac-
count the severity of CS, goals of care, patient-
specific risks, technical limitations, and assess-
ment for futility of care will help develop better
recommendations for MCS choice. Local exper-
tise and comfort with specific measures may
dictate MCS device preference, given the lack
of evidence demonstrating superiority of 1
method over another. Future advances in CS
management are likely to affect the usefulness
of the MCS discussed here. Therefore, it is
important to stay up-to-date on emerging tech-
nologies while maintaining a grasp on older
forms of monitoring in an ever-evolving field.
CLINICS CARE POINTS
 Early invasive hemodynamic monitoring.
 Center expertise.
 Early adoption of MCS based on
pathophysiology.
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